Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01.
In November 2022, the Company submitted an Investigational New Drug Application (“IND”) along with a Fast Track designation application to the FDA for a Phase 2b clinical trial of EVX-01 in combination with KEYTRUDA® for the treatment of patients with metastatic melanoma. On December 22, 2022, the FDA issued approval for the Company to proceed with its Phase 2b trial. The Company anticipates a response to the Fast Track designation submission in the first quarter of 2023.
“Receiving a green light from the FDA is a tremendous boost for our personalized cancer vaccine program. EVX-01 is already actively enrolling patients in Australia, and the FDA approval expands our ability to move forward quickly with our lead program in malignant melanoma. Moreover, the FDA is a universally recognized national authority, and its endorsement is an important step towards demonstrating a clinically meaningful benefit of our first personalized cancer vaccine,” says Erik Heegaard, Chief Medical Officer at Evaxion.
The Phase 2b study will be conducted at clinical sites across the United States, Europe, and Australia. It is carried out in collaboration with Merck, supplying its PD-1 inhibitor KEYTRUDA®. The trial was first initiated in Australia with the enrollment of the first patient in September 2022.
Read about EVX-01 Ph2b on clinicaltrials.gov: NCT05309421.
Evaxion Biotech A/S is a clinical-stage biotech company developing AI-powered immunotherapies. With our proprietary and scalable AI technology, we decode the human immune system to discover and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has a broad pipeline of novel product candidates, including three personalized cancer immunotherapies. It is located in Hørsholm, Denmark, with 70 employees.
Source: Evaxion Biotech
For more information, please contact:
CEO Per Norlén
Katrine Hertz Mortensen
VP, Communications and Public Relations
+45 3010 0203
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Cozycozy is the Only Accommodation Search Engine That Now Includes Airbnb, Giving Travelers the Largest Selection of Vacation Rentals Possible30.1.2023 14:30:00 CET | Press release
One search, so many possibilities - cozycozy helps users find their perfect holiday accommodation from over 100+ booking platforms, including Airbnb. NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cozycozy knows that finding the perfect place to stay can be hard. With the rise of so many vacation rental and hotel platforms comes more and more options, overwhelming travelers. "The days of having multiple tabs open to find the best deal are over," says Romain Claudel, co-founder of cozycozy. "We created cozycozy.com so travelers can see all their options in one place, without all the hassle." There are more and more vacation rentals and hotel rooms listed on several platforms, often with rates that vary. By using cozycozy, users conveniently get the lowest price possible. Their website allows users to see a comprehensive list of available options all at once, so that they get the best rates. They are the only platform in the world to include Airbnb in its search engines, letting users compa
Bank of Åland Plc: Managers' Transactions (Johansson)30.1.2023 14:30:00 CET | Press release
Bank of Åland Plc Managers' Transactions January 30, 2023, 15.30 EET Managers' Transactions --- Person subject to the notification requirement Name: Magnus Johannsson Position: Other senior manager Issuer: Ålandsbanken Abp LEI: 7437006WYM821IJ3MN73 Notification type: INITIAL NOTIFICATION Reference number: 24871/4/4 --- Transaction date: 2023-01-25 Outside a trading venue Instrument type: SHARE ISIN: FI0009001127 Nature of transaction: SUBSCRIPTION Transaction details (1): Volume: 233 Unit price: 32.98 EUR Aggregated transactions (1): Volume: 233 Volume weighted average price: 32.98 EUR For further information, please contact: Peter Wiklöf, Managing Director and Chief Executive, tel +358 40 512 7505
Ålandsbanken Abp: Transaktioner utförda av personer i ledande ställning (Johansson)30.1.2023 14:30:00 CET | Pressemelding
Ålandsbanken Abp Transaktioner utförda av personer i ledande ställning 30.1.2023 kl. 15.30 EET Transaktioner utförda av personer i ledande ställning --- Den anmälningsskyldiga Namn: Magnus Johannsson Befattning: Annan person i högsta ledningen Emittent: Ålandsbanken Abp LEI: 7437006WYM821IJ3MN73 Anmälans karaktär: FÖRSTA ANMÄLAN Referensnummer: 24871/4/4 --- Transaktionens datum: 2023-01-25 Utanför en handelsplats Instrument typ: AKTIE ISIN: FI0009001127 Transaktionens karaktär: TECKNING Detaljer om transaktionerna (1): Volym: 233 Enhetspris: 32.98 EUR Aggregerad information om transaktionerna (1): Volym: 233 Medelpris: 32.98 EUR Ytterligare information: Peter Wiklöf, Vd och koncernchef, Ålandsbanken Abp, tfn +358 40 512 7505
Junshi Biosciences Announces Approval for Marketing of VV116 in China30.1.2023 14:24:07 CET | Press release
SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the “NMPA”) has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001/VV116, “VV116”), an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (“COVID-19”). VV116 is a new oral nucleoside analog antiviral drug, which can be non-covalently bound to the active center of RNA-dependent RNA polymerase (“RdRp”) of SARS-CoV-2 in the form of nucleoside triphosphate, directly inhibiting the activity of RdRp of the virus and blocking the replication of virus, th
Sectigo Announces Automation of AWS and Google Cloud Platform Certificates With Sectigo Certificate Manager30.1.2023 14:00:00 CET | Press release
Leading Public Cloud Certificate Providers Join Sectigo’s Broad Ecosystem of Support Including Microsoft ADCS, Public CAs, and Other Leading Technology Integrations ROSELAND, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Sectigo, a global leader in automated Certificate Lifecycle Management (CLM) and digital certificates, today announced the latest expansion to its industry-leading CLM ecosystem, via Sectigo Certificate Manager (SCM). Organizations can now seamlessly issue and manage digital certificates originating from Google Cloud Platform (GCP), AWS Cloud Services, as well as publicly trusted CAs, providing complete visibility and lifecycle control over all public and private digital certificates within a single platform. This functionality builds upon Sectigo’s already robust capability and enables enterprises to discover, deploy, install, and renew the lifecycles of all digital certificates deployed within an enterprise ecosystem. These additional integrations further deliver on Sectig